SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Yul Brynner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientYul Brynner
Date of birth1920-07-11
IdentifiersMRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572
Document date1983-10-13
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Cycle 2 review on pembrolizumab. [S]

History of Present Illness

Mr. Brynner returns three weeks after his first pembrolizumab infusion, for cycle 2. He felt a little more tired for two days after the infusion and has otherwise felt well. He has had no diarrhea, abdominal pain, new cough or breathlessness, rash or itching, headache, dizziness, thirst, or yellowing. He saw the palliative care team two weeks ago and found the conversation about his goals and his worries useful; he is sleeping better. The injection medialization of his left vocal fold a week ago made his voice louder and less breathy, and he has begun light rehearsal with the voice therapist's exercises. He wants to rejoin the tour for a few performances a week next month. He has had no bone pain and has not smoked. His first zoledronic acid dose is today, with the pembrolizumab. [S]

ElementDetail
Tolerance of cycle 1Two days of extra tiredness; no immune-related symptoms
Palliative careFirst visit two weeks ago
VoiceLouder after injection medialization a week ago; light rehearsal begun
WorkPlans a graded return to the tour next month
Bone symptomsNone

Review of Systems

SystemResultFinding
ConstitutionalPositiveTwo days of extra tiredness after the infusion; no fever
RespiratoryPositiveOccasional morning dry cough, unchanged; no new breathlessness
GastrointestinalNegativeNo diarrhea, abdominal pain, or blood in the stool
IntegumentaryNegativeNo rash or itching
EndocrineNegativeNo headache, dizziness, heat or cold intolerance, or thirst
PsychiatricNegativeMood steady; sleeping better; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeksEvery 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panelIntravenous route1983-09-22activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastasesEvery 12 weeks, after calcium and creatinine, with a dental examination done firstIntravenous route1983-10-13activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acidOne tablet by mouth dailyOral route1983-10-13activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1983-10-13Body height178cmS
1983-10-13Body weight72.2kgS
1983-10-13Body mass index (BMI) [Ratio]22.8kg/m2S
1983-10-13Systolic blood pressure124mm[Hg]S
1983-10-13Diastolic blood pressure76mm[Hg]S
1983-10-13Heart rate76/minS
1983-10-13Respiratory rate16/minS
1983-10-13Body temperature36.7CelS
1983-10-13Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1983-10-13Thyrotropin [Units/volume] in Serum or Plasma2.4m[IU]/L0.4-4 mIU/LNormalS
1983-10-13Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1983-10-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-55 U/LNormalS
1983-10-13Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-48 U/LNormalS
1983-10-13Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
1983-10-13Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-10-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M92mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1983-10-13Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
1983-10-13Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1983-10-13Hemoglobin [Mass/volume] in Blood13.5g/dL13.5-17.5 g/dLNormalS
1983-10-13Leukocytes [#/volume] in Blood by Automated count7.210*3/uL4-11 10*3/uLNormalS
1983-10-13Platelets [#/volume] in Blood by Automated count27010*3/uL150-400 10*3/uLNormalS
1983-10-13Total score [Edmonton Symptom Assessment System]12{score}S
1983-10-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1983-10-13; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 72.2 kg
VoiceLouder and less breathy; longer phonation time
LungsSlightly reduced breath sounds at the left apex; no crackles
SkinNo rash
MouthGood dentition; no exposed bone

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryImmune-related adverse event laboratory panelBefore each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicatedCompleted todayTSH 2.4, free T4 1.1, ALT 30, AST 27, bilirubin 0.7, glucose 104 (non-fasting); no immune-related adverse event
LaboratoryMorning cortisolAt baseline and as indicated by symptoms (ASCO); the CMID lists it before each infusionNot indicatedBaseline 14.2 was normal, and he has no fatigue, dizziness, low blood pressure, or low sodium suggesting adrenal or pituitary injury; repeated if symptoms appear
LaboratoryBlood count, kidney function, and calcium before treatment and before zoledronic acidBefore each cycle and each zoledronic acid doseCompleted todayHemoglobin 13.5, white cells 7.2, platelets 270, creatinine 0.9 (eGFR 92), calcium 9.4
ImagingResponse assessment imagingEvery 6 to 12 weeks on active systemic therapyDueFirst response CT in about six weeks, nine weeks after starting
ExaminationDyspnea and cough assessmentEvery visitCompleted todayOccasional morning cough, unchanged; no new breathlessness to suggest pneumonitis
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker; no tobacco
SurveyDistress and symptom screening (NCCN Distress Thermometer, ESAS)Every visit; at minimum at key transitionsCompleted todayESAS total 12, down from 18; distress thermometer 3 of 10; completed at check-in
SurveyDepression and anxiety screeningAt least yearly; more often during active treatmentCompleted todayPHQ-9 4, item 9 scored 0
SurveyCancer-related fatigue screeningEvery visitCompleted todayTwo days of extra tiredness after cycle 1, then back to his usual
ExaminationWeight and dietary reviewEach follow-upCompleted today72.2 kg, stable
Medication safetyDental evaluation on a bone-modifying agentBaseline, then periodically on zoledronic acid or denosumabUp to dateBaseline examination three weeks ago; routine dental care every six months
ReferralEarly integrated palliative careWithin eight weeks of diagnosis of advanced cancerCompleted todayFirst visit two weeks ago, two weeks after diagnosis; follow-up next month
Self-managementVoice and work supportAs neededCompleted todayInjection medialization a week ago; voice therapy continues; graded return to the tour planned
Medication safetyImmunizations per ACIPYearly reviewDueInfluenza, PCV20, and zoster at the preventive visit in two weeks
Medication safetyChemotherapy-induced peripheral neuropathyEvery visit during and after platinum or taxaneNot indicatedNo platinum or taxane

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)

Follow-up: Pembrolizumab cycle 2 and zoledronic acid today. Preventive visit in two weeks. Cycle 3 in three weeks with the laboratory panel. Response CT about nine weeks after starting. Next scheduled visit 1983-10-27: periodic adult preventive visit. [S]